Formerly dba Optical Coherence Technologies, Inc., Imalux Corporation ceased operations in the Spring 2014. The firm had been commercializing medical imaging equipment and devices based on its proprietary Optical Coherence Tomography (OCT) technology. The Companyâs products provided real-time, high spatial resolution imaging at the point-of-care in a variety of medical applications. OCT is a new imaging modality for visualization of tissue microstructure, especially in anatomical areas with stratified tissue. It has the ability to detect near-surface tissue abnormalities indicative of disease, which established imaging modalities might not detect. Many diseases, including cancer, are associated with superficial tissue structure disruption. Today, there is no commercialized in vivo method to visualize this tissue structure alteration; clinicians must do a biopsy and an ex vivo histopathological review using a conventional microscope. Imalux OCT products can be used to visualize structural disruptions in vivo at the point of car
